Vericel (NASDAQ:VCEL – Get Free Report) and ADMA Biologics (NASDAQ:ADMA – Get Free Report) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, valuation, earnings and dividends.
Volatility and Risk
Vericel has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings for Vericel and ADMA Biologics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vericel | 0 | 0 | 7 | 0 | 3.00 |
| ADMA Biologics | 0 | 0 | 3 | 1 | 3.25 |
Profitability
This table compares Vericel and ADMA Biologics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vericel | 1.56% | 1.48% | 0.96% |
| ADMA Biologics | 17.80% | 53.20% | 26.07% |
Valuation and Earnings
This table compares Vericel and ADMA Biologics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vericel | $226.84 million | 11.42 | -$3.18 million | $0.06 | 874.67 |
| ADMA Biologics | $258.21 million | 17.19 | -$28.24 million | $0.28 | 68.00 |
Vericel has higher earnings, but lower revenue than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
75.7% of ADMA Biologics shares are owned by institutional investors. 5.2% of Vericel shares are owned by company insiders. Comparatively, 3.7% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
ADMA Biologics beats Vericel on 10 of the 15 factors compared between the two stocks.
About Vericel
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
About ADMA Biologics
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.
